Gastrointestinal stromal tumor is rare digestive tract mesenchymal tumor, most often in the wall of the stomach. It is a benign neoplasm, but it can become malignant if not treated. We report a case of gastrointestinal stromal tumor that was discovered after abdominal ultrasonography during staging of a patient with primary cutaneous amelanotic melanoma. Mutation in the tyrosine kinase receptor could explain the development of two types of tumors in the same patient.
INTRODUCTION
Association of gastrointestinal stromal tumor (GIST) with other neoplasms of distinct histological origin is already well docu- and 16% of cases, respectively. Cutaneous MM has a low incidence of mutation in the tyrosine kinase receptor gene (around 9%). 3 To our knowledge, this is the first case reported in the literature of the synchronous existence of amelanotic melanoma (AM) and GIST. We report a patient who was diagnosed with AM and, during the tracing of metastatic lesions, an abdominal tumor was detected, asymptomatic, diagnosed as GIST after resection.
CASE REPORT
A 52-year-old male patient, white, had an erythematous plaque on the right arm, which appeared one year earlier and presented slow growth, with no associated symptoms (he denied gastrointestinal symptoms). The patient had previous history of acute myocardial infarction two years ago. Amelanotic melanoma (AM) is a subtype of primary cutaneous MM that is difficult to diagnose and is defined as a lesion with no pigment at clinical observation. 9, 10 Its incidence is estimated to be between 1.8% and 8.1% of all MMs, including amelanotic and hypomelanotic in this percentage. Clinical presentation can be classified into three types: erythematous macula on skin exposed to the sun, plaque without changes in skin color, and papulonodular lesion (which would be the most frequent form). The low amount of pigment is due to the deficiency of tyrosine enzyme or functional loss in melanin production and storage capacity caused by the rapid cellular differentiation. Prognosis is similar to that of MM, when compared with the same Breslow index, but it is frequently diagnosed later, which worsens the prognosis most of the time. 9 Differential diagnoses include benign, pre-malignant or malignant diseases and the main differential diagnoses are common melanocytic nevi and basal cell carcinoma. 9 Emerging target therapy is very promising for patients with MM, since many mutations have been discovered in melanoma and molecules specifically inhibiting these mutations, as in the case of KIT and BRAF, are already being tested with promising future. 9, 10 We emphasize the importance and the need for new research to clarify the true prevalence and clinical significance of c-KIT gene mutation in melanomas, since target therapy would be an important treatment tool and could modify prognosis of this neoplasm that is so aggressive that is becoming increasingly common in the world. q A B
